electroCore
electroCore, Inc. (Nasdaq: ECOR) is a medical technology company based in Basking Ridge, New Jersey. electroCore was co-founded in 2005 by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD.[1] The current chief executive officer is Daniel S. Goldberger.[2] electroCore[3] has one product called gammaCore,[4][5] a non-invasive, commercially available product that uses vagus nerve stimulation.[6]
History
[edit]The company was co-founded by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD, in 2005.[1]
In 2018, electroCore, Inc. went public with a $78 million IPO.[7]
On March 27, 2020, electroCore announced a common stock purchase agreement of up to $25 million with Chicago-based institutional investor Lincoln Park Capital Fund, LLC.[8]
Products
[edit]gammaCore Sapphire CV
[edit]In July 2020, the FDA gave an emergency COVID-19 authorization for gammaCore Sapphire CV, a vagus nerve stimulation device, aimed at reducing exacerbations in people potentially affected by the novel coronavirus and have difficulty breathing due to asthma.[9]
Truvaga
[edit]A VNS product owned by Electrocore.[10]
References
[edit]- ^ a b "electroCore Inc. Company & People | ECOR". Barron's. Retrieved 2024-12-12.
- ^ "Nerve stimulation device maker electroCore goes public with $78M IPO | FierceBiotech". www.fiercebiotech.com. Retrieved 2019-03-06.
- ^ "This hand-held device is approved to treat cluster headaches". NBC News. Retrieved 2019-03-06.
- ^ "ElectroCore wins cluster headache FDA 510(k) indication for GammaCore". MassDevice. 2018-11-28. Retrieved 2019-03-06.
- ^ "Nerve Stimulator Approved for Cluster Headache". Pain News Network. Retrieved 2019-03-06.
- ^ "Term Sheet -- Friday, June 22". Fortune. Retrieved 2019-03-06.
- ^ Hale, Conor (2018-06-22). "Nerve stimulation device maker electroCore goes public with $78M IPO | Fierce Biotech". www.fiercebiotech.com. Retrieved 2024-12-16.
- ^ "BRIEF-electroCore Announces Common Stock Purchase Agreement For Up To $25 Mln With Lincoln Park Capital". Reuters. 2020-03-27. Retrieved 2020-03-31.
- ^ electroCore (2020-07-13). "electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients". GlobeNewswire News Room. Retrieved 2020-07-15.
- ^ https://www.truvaga.com/vagus-nerve-science/
 | This United States corporation or company article is a stub. You can help Wikipedia by expanding it. |